Claims for Patent: 9,284,300

Summary for Patent: 9,284,300

Title:	Pyridazinone derivatives
Abstract:	Compounds of formula (I) ##STR00001## and their uses as inhibitors of tyrosine kinases, in particular Met kinase, and their employment in methods for the treatment of tumors.
Inventor(s):	Dorsch; Dieter (Ober-Ramstadt, DE), Stieber; Frank (Heidelberg, DE), Schadt; Oliver (Rodenbach, DE), Blaukat; Andree (Muehltal, DE)
Assignee:	Merck Patent GmbH (Darmstadt, DE)
Application Number:	14/496,746
Patent Claims:	1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I or a pharmaceutically acceptable solvate, salt, tautomer or stereoisomer thereof in an amount of 0.5 mg to 1 g per unit dosage, wherein the pharmaceutical composition is in the form of one or more dosage units, ##STR00211## in which R.sup.1 denotes Ar or Het, R.sup.2 denotes pyrimidinyl, which is unsubstituted or mono-, di- or trisubstituted by Hal, A, [C(R.sup.3).sub.2].sub.nOR.sup.3, N.dbd.CR.sup.3N(R.sup.3).sub.2, SR.sup.3, NO.sub.2, CN, COOR.sup.3, CON(R.sup.3).sub.2, NR.sup.3COA, NR.sup.3SO.sub.2A, SO.sub.2N(R.sup.3).sub.2, S(O).sub.mA, [C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nHet, O[C(R.sup.3).sub.2].sub.pOR.sup.3, O[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2,O[C(R.sup.3).sub.2].sub.nC.iden- t.C[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nN.sup.+O.sup.-(R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nHet, S[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, S[C(R.sup.3).sub.2].sub.nHet, NR.sup.3[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, NR.sup.3[C(R.sup.3).sub.2].sub.nHet, NHCON(R.sup.3).sub.2, NHCONH[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, NHCONH[C(R.sup.3).sub.2].sub.nHet, [C(R.sup.3).sub.2].sub.nNHCO[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nNHCO[C(R.sup.3).sub.2].sub.nHet, CON(R.sup.3).sub.2, CONR.sup.3[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, CONR.sup.3[C(R.sup.3).sub.2].sub.nNR.sup.3COOA, CONR.sup.3[C(R.sup.3).sub.2].sub.nOR.sup.3, CONR.sup.3[C(R.sup.3).sub.2].sub.nHet, COHet, COA, CH.dbd.CH--COOR.sup.3, CH.dbd.CH--N(R.sup.3).sub.2 and/or .dbd.O, R.sup.3 denotes H or A, R.sup.4, R.sup.4' each, independently of one another, denote H, Hal, A, OR.sup.3, CN, COOR.sup.3, CON(R.sup.3).sub.2, NR.sup.3COA, NR.sup.3SO.sub.2A, SO.sub.2N(R.sup.3).sub.2 or S(O).sub.m,A, Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, [C(R.sup.3).sub.2].sub.nOR.sup.3, [C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, SR.sup.3, NO.sub.2, CN, COOR.sup.3, CON(R.sup.3).sub.2, NR.sup.3COA, NR.sup.3SO.sub.2A, SO.sub.2N(R.sup.3).sub.2, S(O).sub.m,A, CO--Het, Het,O[C(R3).sub.2].sub.n-N(R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nHet, NHCOOA, NHCON(R.sup.3).sub.2, NHCOO[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, NHCOO[C(R.sup.3).sub.2].sub.nHet, NHCONH[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, NHCONH[C(R.sup.3).sub.2].sub.nHet, OCONH[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, OCONH[C(R.sup.3).sub.2].sub.nHet, CONR.sup.3[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, CONR.sup.3[C(R.sup.3).sub.2].sub.nHet and/or COA, Het denotes a mono-, bi- or tricyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which is unsubstituted or mono-, di-, tri-, tetra- or penta-substituted by Hal, A, [C(R.sup.3).sub.2].sub.nOR.sup.3, [C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, SR.sup.3, NO.sub.2, CN, COOR.sup.3, CON(R.sup.3).sub.2, NR.sup.3COA, NR.sup.3SO.sub.2A, SO.sub.2N(R.sup.3).sub.2, S(O).sub.m,A, CO--Het.sup.1, [C(R.sup.3).sub.2].sub.nHet.sup.1, O[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nHet.sup.1, NHCOOA, NHCON(R.sup.3).sub.2, NHCOO[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, NHCOO[C(R.sup.3).sub.2].sub.nHet.sup.1, NHCONH[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, NHCONH[C(R.sup.3).sub.2].sub.nHet.sup.1, OCONH[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, OCONH[C(R.sup.3).sub.2].sub.nHet.sup.1, CO--Het.sup.1, CHO, COA, .dbd.S, .dbd.NH, .dbd.NA and/or .dbd.O and where a ring nitrogen is optionally oxidized, Het.sup.1 denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which is unsubstituted or mono- or disubstituted by A, OA, OH, Hal and/or .dbd.O, A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms are optionally replaced by F and/or in which one or two non-adjacent CH.sub.2 groups are optionally replaced by O, NH, S, SO, SO.sub.2 and/or by CH.dbd.CH groups, or cyclic alkyl having 3-7 C atoms, Hal denotes F, Cl, Br or I, m denotes 0, 1 or 2, n denotes 0, 1, 2, 3 or 4, and p denotes 1, 2, 3 or 4. 2. A pharmaceutical composition according to claim 1, which comprises a compound of formula I or a pharmaceutically acceptable solvate, salt, tautomer or stereoisomer thereof in an amount of 1 mg to 700 mg per unit dosage. 3. A pharmaceutical composition according to claim 1, which is in the form of a single dosage unit. 4. A pharmaceutical composition according to claim 1, which comprises a compound of formula I or a pharmaceutically acceptable salt thereof. 5. A pharmaceutical composition according to claim 1, wherein in the compound of formula I R.sup.2 denotes pyrimidinyl, which is monosubstituted by Hal, A, [C(R.sup.3).sub.2].sub.nOR.sup.3, N.dbd.CR.sup.3N(R.sup.3).sub.2, CN, COOR.sup.3, [C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nHet, O[C(R.sup.3).sub.2].sub.pOR.sup.3, O[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nC.ident.C[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.- 2, O[C(R.sup.3).sub.2].sub.nN.sup.+O.sup.31 (R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nHet, NR.sup.3[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, NR.sup.3[C(R.sup.3).sub.2].sub.nHet, [C(R.sup.3).sub.2].sub.nNHCO[C(R.sup.3).sub.2].sub.n-N(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nNHCO[C(R.sup.3).sub.2].sub.nHet, CONR.sup.3[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, CONR.sup.3[C(R.sup.3).sub.2].sub.nNR.sup.3COOA, CONR.sup.3[C(R.sup.3).sub.2].sub.nOR.sup.3, CONR.sup.3[C(R.sup.3).sub.2].sub.nHet, COHet, CH.dbd.CH--COOR.sup.3, CH.dbd.CH--N(R.sup.3).sub.2 and/or .dbd.O. 6. A pharmaceutical composition according to claim 1, wherein in the compound of formula I Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, S(O).sub.m,A, NR.sup.3COA, CON(R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nOR.sup.3, CONR.sup.3[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2 and/or CONR.sup.3[C(R.sup.3).sub.2].sub.nHet. 7. A pharmaceutical composition according to claim 1, wherein in the compound of formula I R.sup.1 denotes Ar or Het, R.sup.2 denotes pyrimidinyl, which is unsubstituted or mono-, di- or trisubstituted by Hal, A, [C(R.sup.3).sub.2].sub.nOR.sup.3, N.dbd.CR.sup.3N(R.sup.3).sub.2, CN, COOR.sup.3, [C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nHet, O[C(R.sup.3).sub.2].sub.pOR.sup.3, O[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nC.ident.C[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.- 2, O[C(R.sup.3).sub.2].sub.nN.sup.+O.sup.31(R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nHet, NR.sup.3[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, NR.sup.3[C(R.sup.3).sub.2].sub.nHet, [C(R.sup.3).sub.2].sub.nNHCO[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nNHCO[C(R.sup.3).sub.2].sub.nHet, CONR.sup.3[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, CONR.sup.3[C(R.sup.3).sub.2].sub.nNR.sup.3COOA, CONR.sup.3[C(R.sup.3).sub.2].sub.nOR.sup.3, CONR.sup.3[C(R.sup.3).sub.2].sub.nHet, COHet, CH.dbd.CH--COOR.sup.3, CH.dbd.CH--N(R.sup.3).sub.2 and/or .dbd.O, R.sup.3 denotes H, methyl, ethyl or propyl, R.sup.4, R.sup.4' denote H, Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, S(O).sub.m,A, NR.sup.3COA, CON(R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nOR.sup.3, CONR.sup.3[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2 and/or CONR.sup.3[C(R.sup.3).sub.2].sub.nHet, Het denotes piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, benzimidazolyl, benzotriazolyl, indolyl, benzo-1,3-dioxolyl, indazolyl, azabicyclo[3.2.11]octyl, azabicyclo[2.2.2]octyl, imidazolidinyl, azepanyl or benzo-2,1,3-thiadiazolyl, each of which is unsubstituted or mono-, di-, tri-, tetra- or penta-substituted by A, CHO, COOR.sup.3, CON(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nHet.sup.1, [C(R.sup.3).sub.2].sub.nOR.sup.3, [C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nHet.sup.1 and/or .dbd.O, and where a ring nitrogen is optionally oxidized, Het.sup.1 denotes pyrrolidine, piperidine, piperazine or morpholine, each of which is unsubstituted or mono- or disubstituted by A and/or .dbd.O, A denotes unbranched or branched alkyl having 1-8 C atoms, in which 1-7 H atoms are optionally replaced by F, Hal denotes F, Cl, Br or I, m denotes 0, 1 or 2, n denotes 0, 1, 2, 3 or 4, and p denotes 1, 2, 3 or 4. 8. A pharmaceutical composition according to claim 1, wherein in the compound of formula I R.sup.2 is pyrimidinyl, which is monosubstituted by Hal, A, [C(R.sup.3).sub.2].sub.nOR.sup.3, N.dbd.CR.sup.3N(R.sup.3).sub.2, SR.sup.3, NO.sub.2, CN, COOR.sup.3, CON(R.sup.3).sub.2, NR.sup.3COA, NR.sup.3SO.sub.2A, SO.sub.2N(R.sup.3).sub.2, S(O).sub.m,A, [C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nHet, O[C(R.sup.3).sub.2].sub.pOR.sup.3, O[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nC.ident.C[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.- 2, O[C(R.sup.3).sub.2].sub.nN.sup.+O.sup.31 (R.sup.3).sub.2, O [C(R.sup.3).sub.2].sub.nHet, S[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, S [C(R.sup.3).sub.2].sub.nHet, NR.sup.3[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, NR.sup.3[C(R.sup.3).sub.2].sub.nHet, NHCON(R.sup.3).sub.2, NHCONH[C(R.sup.3).sub.2].sub.n-N(R.sup.3).sub.2, NHCONH[C(R.sup.3).sub.2].sub.nHet, [C(R.sup.3).sub.2].sub.nNHCO[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nNHCO[C(R.sup.3).sub.2].sub.n-Het, CON(R.sup.3).sub.2, CONR.sup.3[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, CONR.sup.3[C(R.sup.3).sub.2].sub.nNR.sup.3COOA, CONR.sup.3 [C(R.sup.3).sub.2].sub.nOR.sup.3, CONR.sup.3 [C(R.sup.3).sub.2].sub.nHet, COHet, COA, CH.dbd.CH--COOR.sup.3, CH.dbd.CH--N(R.sup.3).sub.2 and/or .dbd.O. 9. A pharmaceutical composition according to claim 1, wherein in the compound of formula I R.sup.1 denotes Ar or Het, R.sup.2 denotes pyrimidinyl, which is monosubstituted by Hal, A, [C(R.sup.3).sub.2].sub.nOR.sup.3, N.dbd.CR.sup.3N(R.sup.3).sub.2, CN, COOR.sup.3, [C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nHet, O[C(R.sup.3).sub.2].sub.pOR.sup.3, O[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nC.ident.C[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.- 2, O[C(R.sup.3).sub.2].sub.nN.sup.+O.sup.31 (R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nHet, NR.sup.3[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, NR.sup.3[C(R.sup.3).sub.2].sub.nHet, [C(R.sup.3).sub.2].sub.nNHCO[C(R.sup.3).sub.2].sub.n-N(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nNHCO[C(R.sup.3).sub.2].sub.nHet, CONR.sup.3[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, CONR.sup.3[C(R.sup.3).sub.2].sub.nNR.sup.3COOA, CONR.sup.3[C(R.sup.3).sub.2].sub.nOR.sup.3, CONR.sup.3[C(R.sup.3).sub.2].sub.nHet, COHet, CH.dbd.CH--COOR.sup.3, CH.dbd.CH--N(R.sup.3).sub.2 and/or .dbd.O, R.sup.3 denotes H, methyl, ethyl or propyl, R.sup.4, R.sup.4' denote H, Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, S(O).sub.m,A, NR.sup.3COA, CON(R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nOR.sup.3, CONR.sup.3[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2 and/or CONR.sup.3[C(R.sup.3).sub.2].sub.nHet, Het denotes piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, benzimidazolyl, benzotriazolyl, indolyl, benzo-1,3-dioxolyl, indazolyl, azabicyclo[3.2.11]octyl, azabicyclo[2.2.2]octyl, imidazolidinyl, azepanyl or benzo-2,1,3-thiadiazolyl, each of which is unsubstituted or mono-, di-, tri-, tetra- or penta-substituted by A, CHO, COOR.sup.3, CON(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nHet.sup.1, [C(R.sup.3).sub.2].sub.nOR.sup.3, [C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nHet.sup.1 and/or .dbd.O, and where a ring nitrogen is optionally oxidized, Het.sup.1 denotes pyrrolidine, piperidine, piperazine or morpholine, each of which is unsubstituted or mono- or disubstituted by A and/or .dbd.O, A denotes unbranched or branched alkyl having 1-8 C atoms, in which 1-7 H atoms are optionally replaced by F, Hal denotes F, Cl, Br or I, m denotes 0, 1 or 2, n denotes 0, 1, 2, 3 or 4, and p denotes 1, 2, 3 or 4, or a pharmaceutically acceptable solvate, salt, tautomer or stereoisomer thereof. 10. A pharmaceutical composition according to claim 1, wherein in the compound of formula I R.sup.1 denotes Ar or Het, R.sup.2 denotes pyrimidinyl, which is monosubstituted by Hal, A, [C(R.sup.3).sub.2].sub.nOR.sup.3, N.dbd.CR.sup.3N(R.sup.3).sub.2, CN, COOR.sup.3, [C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nHet, O[C(R.sup.3).sub.2].sub.pOR.sup.3, O[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nC.ident.C[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.- 2, O[C(R.sup.3).sub.2].sub.nN.sup.+O.sup.31 (R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nHet, NR.sup.3[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, NR.sup.3[C(R.sup.3).sub.2].sub.nHet, [C(R.sup.3).sub.2].sub.nNHCO[C(R.sup.3).sub.2].sub.n-N(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nNHCO[C(R.sup.3).sub.2].sub.nHet, CONR.sup.3[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, CONR.sup.3[C(R.sup.3).sub.2].sub.nNR.sup.3COOA, CONR.sup.3[C(R.sup.3).sub.2].sub.nOR.sup.3, CONR.sup.3[C(R.sup.3).sub.2].sub.nHet, COHet, CH.dbd.CH--COOR.sup.3, CH.dbd.CH--N(R.sup.3).sub.2 and/or .dbd.O, R.sup.3 denotes H, methyl, ethyl or propyl, R.sup.4, R.sup.4' denote H, Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, S(O).sub.m,A, NR.sup.3COA, CON(R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nOR.sup.3, CONR.sup.3[C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2 and/or CONR.sup.3[C(R.sup.3).sub.2].sub.nHet, Het denotes piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, benzimidazolyl, benzotriazolyl, indolyl, benzo-1,3-dioxolyl, indazolyl, azabicyclo[3.2.1]octyl, azabicyclo[2.2.2]octyl, imidazolidinyl, azepanyl or benzo-2,1,3-thiadiazolyl, each of which is unsubstituted or mono-, di-, tri-, tetra- or penta-substituted by A, CHO, COOR.sup.3, CON(R.sup.3).sub.2, [C(R.sup.3).sub.2].sub.nHet.sup.1, [C(R.sup.3).sub.2].sub.nOR.sup.3, [C(R.sup.3).sub.2].sub.nN(R.sup.3).sub.2, O[C(R.sup.3).sub.2].sub.nHet.sup.1 and/or .dbd.O, and where a ring nitrogen is optionally oxidized, Het.sup.1 denotes pyrrolidine, piperidine, piperazine or morpholine, each of which is unsubstituted or mono- or disubstituted by A and/or .dbd.O, A denotes unbranched or branched alkyl having 1-8 C atoms, in which 1-7 H atoms are optionally replaced by F, Hal denotes F, Cl, Br or I, m denotes 0, 1 or 2, n denotes 0, 1, 2, 3 or 4, and P denotes 1, 2, 3 or 4. 11. A pharmaceutical composition according to claim 1, which comprises 3-(1-{3-[5-(1-methylpiperidin-4-ylmethoxy)pyrimidin-2-yl]benzyl}-6-oxo-1,- 6-dihydropyridazin-3-yl)benzonitrile or a pharmaceutically acceptable solvate, salt, tautomer or stereoisomer thereof. 12. A pharmaceutical composition according to claim 1, which comprises 3-(1-{3-[5-(1-methylpiperidin-4-ylmethoxy)pyrimidin-2-yl]benzyl }-6- oxo-1,6-dihydropyridazin-3-yl)benzonitrile or a pharmaceutically acceptable salt thereof. 13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one of the compounds below or a pharmaceutically acceptable solvate, salt, tautomer or stereoisomer thereof in an amount of 0.5 mg to 1 g per unit dosage, wherein the pharmaceutical composition is in the form of one or more dosage units TABLE-US-00020 No. Name and/or structure "A1" 2-[3-(5-methylpyrimidin-2-yl)benzyl]-6-(3,4,5-trifluorophenyl)-2H-pyr- idazin-3-one "A2" 6-(3,5-difluorophenyl)-2-[3-(5-methylpyrimidin-2-yl)benzyl]-2H-pyrida- zin-3-one "A3" 2-[3-(4-methylpyrimidin-2-yl)benzyl]-6-(3,4,5-trifluorophenyl)-2H-pyr- idazin-3-one "A4" 2-(3-pyrimidin-2-ylbenzyl)-6-(3,4,5-trifluorophenyl)-2H-pyridazin-3-o- ne "A13" 6-(3,5-difluorophenyl)-2-[3-(4-piperazin-1-ylpyrimidin-2-yl)-benzyl]- -2H-pyridazin-3-one "A14" 6-(3,5-difluorophenyl)-2-{3-[5-(4-methylpiperazin-1-ylmethyl)-pyrimi- din-2-yl]benzyl}-2H-pyridazin-3-one "A15" 3-{1-[3-(5-methylpyrimidin-2-yl)benzyl]-6-oxo-1,6-dihydro-pyridazin-- 3-yl}benzonitrile "A16" N'-(2-{3-[3-(3,5-difluorophenyl)-6-oxo-6H-pyridazin-1-ylmethyl]-phen- yl}pyrimidin-5-yl)-N,N-dimethylformamidine "A17" 2-[3-(5-aminopyrimidin-2-yl)benzyl]-6-(3,5-difluorophenyl)-2H-pyrida- zin-3-one "A18" 6-(3,5-difluorophenyl)-2-{3-[5-(4-methylpiperazin-1-yl)pyrimidin-2-y- l]benzyl}-2H-pyridazin-3-one "A19" 6-(3,5-difluorophenyl)-2-[3-(5-piperazin-1-ylpyrimidin-2-yl)-benzyl]- -2H-pyridazin-3-one "A20" 2-{3-[5-(4-methylpiperazin-1-yl)pyrimidin-2-yl]benzyl}-6-(3,4,5-trif- luorophenyl)-2H-pyridazin-3-one "A21" 6-(3,5-difluorophenyl)-2-[3-(5-hydroxypyrimidin-2-yl)benzyl]-2H-pyri- dazin-3-one "A22" 6-(3,5-difluorophenyl)-2-{3-[5-(3-dimethylaminopropoxy)-pyrimidin-2-- yl]benzyl}-2H-pyridazin-3-one "A23" ##STR00212## "A25" 2-[3-(5-bromopyrimidin-2-yl)benzyl]-6-(3,5-difluorophenyl)-2H-pyrida- zin-3-one "A26" 6-(3,5-difluorophenyl)-2-{3-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-- 2-yl]benzyl}-2H-pyridazin-3-one "A29" ethyl 2-{3-[6-oxo-3-(3,4,5-trifluorophenyl)-6H-pyridazin-1-ylmethyl]phenyl}pyri- midine-5-carboxylate "A30" ##STR00213## "A31" 2-{3-[6-oxo-3-(3,4,5-trifluorophenyl)-6H-pyridazin-1-ylmethyl]-pheny- l}pyrimidine-5-carboxylic acid "A32" 2-{3-[3-(3,5-difluorophenyl)-6-oxo-6H-pyridazin-1-ylmethyl]-phenyl}p- yrimidine-5-carboxylic acid "A33" N-(2-dimethylaminoethyl)-2-{3-[6-oxo-3-(3,4,5-trifluorophenyl)-6H-py- ridazin-1-ylmethyl]phenyl}pyrimidine-5- carboxamide "A34" ##STR00214## "A35" ##STR00215## "A36" ##STR00216## "A37" ##STR00217## "A38" ##STR00218## "A39" ##STR00219## "A40" ##STR00220## "A41" ##STR00221## "A42" ##STR00222## "A43" ##STR00223## "A44" ##STR00224## "A44a" ##STR00225## "A45" ##STR00226## "A46" ##STR00227## "A47" ##STR00228## "A48" ##STR00229## "A49" ##STR00230## "A50" ##STR00231## "A51" N-[2-(1H-imidazol-4-yl)ethyl]-2-{3-[6-oxo-3-(3,4,5-trifluoro-phenyl)- -6H-pyridazin-1-ylmethyl]phenyl}pyrimidine-5- carboxamide "A52" ##STR00232## "A53" ##STR00233## "A54" 2-[3-(5-chloropyrimidin-2-yl)benzyl]-6-(3,4,5-trifluorophenyl)-2H-py- ridazin-3-one "A55" 4-{1-[3-(5-methylpyrimidin-2-yl)benzyl]-6-oxo-1,6-dihydro-pyridazin-- 3-yl}-N-(3-piperidin-1-ylpropyl)benzamide "A56" 6-(3,5-difluorophenyl)-2-{3-[5-(3-pyrrolidin-1-ylpropoxy)-pyrimidin-- 2-yl]benzyl}-2H-pyridazin-3-one "A57" 6-(3,5-difluorophenyl)-2-(3-{5-[2-(4-methylpiperazin-1-yl)-ethoxy]py- rimidin-2-yl}benzyl)-2H-pyridazin-3-one "A58" 6-(3,5-difluorophenyl)-2-[3-(5-dimethylaminomethylpyrimidin-2-yl)ben- zyl]-2H-pyridazin-3-one "A59" ##STR00234## "A60" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-(3,4,5-trif- luorophenyl)-2H-pyridazin-3-one "A63" ##STR00235## "A64" 2-{3-[5-(2-dimethylaminoethoxy)pyrimidin-2-yl]benzyl}-6-(3,5-difluor- ophenyl)-2H-pyridazin-3-one "A65" 2-{3-[5-(piperazin-1-yl)pyrimidin-2-yl]benzyl}-6-(3,4,5-trifluoro-ph- enyl)-2H-pyridazin-3-one "A66" 6-(3,5-difluorophenyl)-2-{3-[5-(1-methylpiperidin-4-ylmethoxy)-pyrim- idin-2-yl]benzyl}-2H-pyridazin-3-one "A71" ##STR00236## "A72" ##STR00237## "A73" ##STR00238## "A74" ##STR00239## "A75" ##STR00240## "A76" N'-(2-{3-[3-(3,4,5-trifluorophenyl)-6-oxo-6H-pyridazin-1-yl-methyl]p- henyl}pyrimidin-5-yl)-N,N-dimethylformannidine "A77" ##STR00241## "A78" ##STR00242## "A79" ##STR00243## "A80" 6-(3,5-difluorophenyl)-2-[3-(6-oxo-1,6-dihydropyrimidin-2-yl)-benzyl- ]-2H-pyridazin-3-one "A81" 6-(3,5-difluorophenyl)-2-{3-[4-(3-dimethylaminopropoxy)-pyrimidin-2-- yl]benzyl}-2H-pyridazin-3-one "A82" 2-[3-(5-aminopyrimidin-2-yl)benzyl]-6-(3,4,5-trifluorophenyl)-2H-pyr- idazin-3-one "A83" 2-(3-pyrimidin-5-ylbenzyl)-6-(3,4,5-trifluorophenyl)-2H-pyridazin-3-- one "A84" ##STR00244## "A85" N-(2-{3-[3-(3,5-difluorophenyl)-6-oxo-6H-pyridazin-1-ylmethyl]-pheny- l}pyrimidin-5-yl)-2-dimethylaminoacetamide "A87" ##STR00245## "A88" ##STR00246## "A89" ##STR00247## "A90" ##STR00248## "A92" ##STR00249## "A93" 2-[3-(5-aminomethylpyrimidin-2-yl)benzyl]-6-(3,4,5-trifluoro-phenyl)- -2H-pyridazin-3-one "A95" ##STR00250## "A96" ##STR00251## "A97" ##STR00252## "A98" ##STR00253## "A99" ##STR00254## "A100" 2-[3-(5-methylpyrimidin-2-yl)benzyl]-6-(2H-pyrazol-3-yl)-2H-pyridaz- in-3-one "A101" 6-(3,5-difluorophenyl)-2-[3-(5-hydroxymethylpyrimidin-2-yl)-benzyl]- -2H-pyridazin-3-one "A102" 6-(3,5-difluorophenyl)-2-{3-[5-(piperidin-4-yloxy)pyrimidin-2-yl]-b- enzyl}-2H-pyridazin-3-one "A103" ##STR00255## "A104" ##STR00256## "A105" ##STR00257## "A106" ##STR00258## "A107" ##STR00259## "A108" ##STR00260## "A109" ##STR00261## "A110" ##STR00262## "A111" ##STR00263## "A112" ##STR00264## "A113" ##STR00265## "A114" ##STR00266## "A115" ##STR00267## "A116" ##STR00268## "A117" ##STR00269## "A118" ##STR00270## "A119" ##STR00271## "A120" ##STR00272## "A121" ##STR00273## "A122" 6-(3,5-difluorophenyl)-2-{3-[5-((R)-1-methylpyrrolidin-3-yloxy)-pyr- imidin-2-yl]benzyl}-2H-pyridazin-3-one, "A123" ##STR00274## "A124" ##STR00275## "A125" ##STR00276## "A126" ##STR00277## "A127" 6-(3,5-difluorophenyl)-2-{3-[5-(2-pyrrolidin-1-ylethoxy)-pyrimidin-- 2-yl]benzyl}-2H-pyridazin-3-one "A128" 6-(3,5-difluorophenyl)-2-{3-[5-(3-morpholin-4-ylpropoxy)-pyrimidin-- 2-yl]benzyl}-2H-pyridazin-3-one "A129" ##STR00278## "A130" 6-(3,5-difluorophenyl)-2-{3-[5-(2-morpholin-4-ylethoxy)-pyrimidin-2- -yl]benzyl}-2H-pyridazin-3-one, hydrochloride "A131" ##STR00279## "A132" 6-(3,5-difluorophenyl)-2-{3-[5-(4-methylaminobutoxy)pyrimidin-2-yl]- benzyl}-2H-pyridazin-3-one "A133" 6-(3,5-difluorophenyl)-2-{3-[5-(3-methylaminopropoxy)-pyrimidin-2-y- l]benzyl}-2H-pyridazin-3-one "A134" 6-(3,5-difluorophenyl)-2-{3-[5-(pyrrolidin-3-ylmethoxy)-pyrimidin-2- -yl]benzyl}-2H-pyridazin-3-one "A135" 6-(3,5-difluorophenyl)-2-{3-[5-(3-ethylaminopropoxy)pyrimidin-2-yl]- benzyl}-2H-pyridazin-3-one "A136" 2-{3-[5-(2-aminoethoxy)pyrimidin-2-yl]benzyl1-6-(3,5-difluoro-pheny- l)-2H-pyridazin-3-one "A137" 6-(3,5-difluorophenyl)-2-{3-[5-(piperidin-3-yloxy)pyrimidin-2-yl]-b- enzyl}-2H-pyridazin-3-one "A138" 6-(3,5-difluorophenyl)-2-{3-[5-(piperidin-4-ylmethoxy)pyrimidin-2-y- l]benzyl}-2H-pyridazin-3-one "A139" 6-(3,5-difluorophenyl)-2-{3-[5-(pyrrolidin-3-yloxy)pyrimidin-2-yl]b- enzyl}-2H-pyridazin-3-one "A140" 6-(3,5-difluorophenyl)-2-{3-[5-((S)-pyrrolidin-3-yloxy)pyrimidin-2-- yl]benzyl}-2H-pyridazin-3-one "A141" 6-(3,5-difluorophenyl)-2-{3-[5-((R)-pyrrolidin-3-yloxy)pyrimidin-2-- yl]benzyl}-2H-pyridazin-3-one "A142" ##STR00280## "A143" ##STR00281## "A144" 3-(6-oxo-1-{3-[5-(piperidin-4-yloxy)pyrimidin-2-yl]benzyl}-1,6-dihy- dropyridazin-3-yl)benzonitrile "A145" 6-(3,5-difluorophenyl)-2-{3-[5-(2-piperazin-1-ylethoxy)pyrimidin-2-- yl]benzyl}-2H-pyridazin-3-one "A146" 6-(3,5-difluorophenyl)-2-{3-[5-(piperidin-4-yloxy)pyrimidin-2-yl]-b- enzyl}-2H-pyridazin-3-one "A147" 3-(6-oxo-1-{3-[5-(2-piperazin-1-ylethoxy)pyrimidin-2-yl]benzyl}-1,6- -dihydropyridazin-3-yl)benzonitrile "A148" 6-(3-fluorophenyl)-2-{3-[5-(piperidin-4-ylmethoxy)pyrimidin-2-yl]be- nzyl}-2H-pyridazin-3-one "A149" ##STR00282## "A150" ##STR00283## "A151" ##STR00284## "A152" 6-(3-methoxyphenyl)-2-{3-[5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyri- midin-2-yl]benzyl}-2H-pyridazin-3-one "A153" 6-(3-fluorophenyl)-2-{3-[5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyrim- idin-2-yl]benzyl}-2H-pyridazin-3-one "A154" ##STR00285## "A155" ##STR00286## "A156" ##STR00287## "A157" ##STR00288## "A158" ##STR00289## "A159" ##STR00290## "A160" ##STR00291## "A161" ##STR00292## "A162" ##STR00293## "A163" ##STR00294## "A164" ##STR00295## "A165" ##STR00296## "A166" ##STR00297## "A167" ##STR00298## "A168" ##STR00299## "A169" ##STR00300## "A170" ##STR00301## "A171" ##STR00302## "A172" 6-(3,5-difluorophenyl)-2-(3-{5-[1-(3-dimethylaminopropyl)-1H-pyrazo- l-4-yl]pyrimidin-2-yl]benzyl)-2H-pyridazin-3-one "A173" 6-(3,5-difluorophenyl)-2-(3-{5-[1-(2-pyrrolidin-1-ylethyl)-1H-pyraz- ol-4-yl]pyrimidin-2-yl]benzyl)-2H-pyridazin-3-one "A174" ##STR00303## "A175" ##STR00304## "A176" ##STR00305## "A177" 2-(3-{5-[1-(2-morpholin-4-ylethyl)-1H-pyrazol-4-yl]pyrimidin-2-yl}b- enzyl)-6-pyridin-4-yl-2H-pyridazin-3-one "A178" 6-(4-methanesulfonylphenyl)-2-(3-{5-[1-(2-morpholin-4-ylethyl)-1H-p- yrazol-4-yl]pyrimidin-2-yl]benzyl)-2H-pyridazin-3- one "A179" 6-pyridin-4-yl-2-(3-{5-[1-(2-pyrrolidin-1-ylethyl)-1H-pyrazol-4-yl]- pyrimidin-2-yl]benzyl)-2H-pyridazin-3-one "A180" ##STR00306## "A181" 2-(3-{5-[1-(2-morpholin-4-ylethyl)-1H-pyrazol-4-yl]pyrimidin-2-yl}b- enzyl)-6-pyridin-4-yl-2H-pyridazin-3-one "A182" ##STR00307## "A183" 6-(4-methanesulfonylphenyl)-2-(3-{5-[1-(2-morpholin-4-ylethyl)-1H-p- yrazol-4-yl]pyrimidin-2-yl}benzyl)-2H-pyridazin-3- one "A184" ##STR00308## "A185" 6-(3-fluorophenyl)-2-(3-{5-[1-(2-pyrrolidin-1-ylethyl)-1H-pyrazol-4- -yl]pyrimidin-2-yl}benzyl)-2H-pyridazin-3-one "A186" ##STR00309## "A187" ##STR00310## "A188" ##STR00311## "A188a" ##STR00312## "A189" 3-(1-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-oxo-1,6- -dihydropyridazin-3-yl)benzonitrile "A190" ##STR00313## "A191" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-(3-fluorop- henyl)-2H-pyridazin-3-one "A192" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-thiazol-2-- yl-2H-pyridazin-3-one "A193" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-phenyl-2H-- pyridazin-3-one "A194" 4-(1-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-oxo-1,6- -dihydropyridazin-3-yl)benzonitrile "A195" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-p-tolyl-2H- -pyridazin-3-one "A196" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-(2H-pyrazo- l-3-yl)-2H-pyridazin-3-one "A197" 6-(3,4-difluorophenyl)-2-{3-[5-(3-dimethylaminopropoxy)-pyrimidin-2- -yl]benzyl}-2H-pyridazin-3-one "A198" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-(4-methane- sulfonylphenyl)-2H-pyridazin-3-one "A199" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-[4-(5-meth- yl-1,2,4-oxadiazol-3-yl)phenyl]-2H-pyridazin-3-one "A200" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-pyridin-4-- yl-2H-pyridazin-3-one "A201" 6-(3-bromophenyl)-2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]be- nzyl}-2H-pyridazin-3-one "A202" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-(3,4,5-tri- fluorophenyl)-2H-pyridazin-3-one "A203" 6-(3,5-dimethoxyphenyl)-2-{3-[5-(3-dimethylaminopropoxy)-pyrimidin-- 2-yl]benzyl}-2H-pyridazin-3-one "A204" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-(3-fluoro-- 4-methoxyphenyl)-2H-pyridazin-3-one "A205" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-(4-methoxy- phenyl)-2H-pyridazin-3-one "A206" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-(3-trifluo- romethylphenyl)-2H-pyridazin-3-one, "A207" 6-(3-chlorophenyl)-2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]b- enzyl}-2H-pyridazin-3-one "A208" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-pyridin-3-- yl-2H-pyridazin-3-one "A209" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-(1-methyl-- 1H-pyrazol-4-yl)-2H-pyridazin-3-one "A210" 6-(3-chloro-5-fluorophenyl)-2-{3-[5-(3-dimethylaminopropoxy)-pyrimi- din-2-yl]benzyl}-2H-pyridazin-3-one "A211" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-(4-fluoro-- 3-methoxyphenyl)-2H-pyridazin-3-one "A212" 6-(4-chlorophenyl)-2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]b- enzyl}-2H-pyridazin-3-one "A213" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-(4-fluorop- henyl)-2H-pyridazin-3-one "A214" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-thiophen-2- -yl-2H-pyridazin-3-one "A215" ##STR00314## "A216" 6-(3,4-dimethoxyphenyl)-2-{3-[5-(3-dimethylaminopropoxy)-pyrimidin-- 2-yl]benzyl}-2H-pyridazin-3-one "A217" ##STR00315## "A218" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-furan-3-yl- -2H-pyridazin-3-one "A219" 2-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-(5-methyl-- 1,2,4-oxadiazol-3-yl)-2H-pyridazin-3-one "A220" 4-(1-{3-[5-(1-methylpiperidin-4-yloxy)pyrimidin-2-yl]benzyl}-6-oxo-- 1,6-dihydropyridazin-3-yl)benzonitrile "A221" 3-(1-{3-[5-(1-methylpiperidin-4-yloxy)pyrimidin-2-yl]benzyl}-6-oxo-- 1,6-dihydropyridazin-3-yl)benzonitrile "A222" 3-(1-{3-[5-(2-morpholin-4-ylethoxy)pyrimidin-2-yl]benzyl}-6-oxo-1,6- -dihydropyridazin-3-yl)benzonitrile "A223" 2-{3-[5-(1-methylpiperidin-4-yloxy)pyrimidin-2-yl]benzyl}-6-pyridin- -4-yl-2H-pyridazin-3-one "A224" 6-(4-methanesulfonylphenyl)-2-{3-[5-(1-methylpiperidin-4-yloxy)-pyr- imidin-2-yl]benzyl}-2H-pyridazin-3-one "A225" ##STR00316## "A226" 2-{3-[5-(1-methylpiperidin-4-yloxy)pyrimidin-2-yl]benzyl}-6-(1-meth- yl-1H-pyrazol-4-yl)-2H-pyridazin-3-one "A227" ##STR00317## "A228" ##STR00318## "A229" 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-ylethoxy)-pyrim- idin-2-yl]benzyl}-2H-pyridazin-3-one "A230" 2-[3-(5-bromopyrimidin-2-yl)benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-2H- -pyridazin-3-one "A231" 2-[3-(5-hydroxypyrimidin-2-yl)benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-- 2H-pyridazin-3-one "A235" 6-(3-fluorophenyl)-2-{3-[5-(2-morpholin-4-ylethoxy)pyrimidin-2-yl]b- enzyl}-2H-pyridazin-3-one "A237" 2-{3-[5-(1-methylpiperidin-4-ylmethoxy)pyrimidin-2-yl]benzyl}-6-(1-- methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one "A238" 2-{3-[5-(1-methylpiperidin-4-yloxy)pyrimidin-2-yl]benzyl}-6-(1-meth- yl-1H-pyrazol-4-yl)-2H-pyridazin-3-one "A239" 2-[3-(5-methoxypyrimidin-2-yl)benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-- 2H-pyridazin-3-one "A240" 2-{3-[5-(3-methoxypropoxy)pyrimidin-2-yl]benzyl}-6-(1-methyl-1H-pyr- azol-4-yl)-2H-pyridazin-3-one "A241" 2-{3-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzyl}-6-(1-methyl-1H-pyra- zol-4-yl)-2H-pyridazin-3-one "A242" 2-{3-[5-(2-morpholin-4-ylethoxy)pyrimidin-2-yl]benzyl}-6-(1-propyl-- 1H-pyrazol-4-yl)-2H-pyridazin-3-one "A243" 2-(3-{5-[2-(4-methylpiperazin-1-yl)ethoxy]pyrimidin-2-yl)-benzyl)-6- -(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one "A244" ##STR00319## "A245" 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(3-morpholin-4-ylpropoxy)-pyri- midin-2-yl]benzyl1-2H-pyridazin-3-one "A246" ##STR00320## "A247" ##STR00321## "A248" 2-{3-[5-(2-dimethylaminoethoxy)pyrimidin-2-yl]benzyl1-6-(1-methyl-1- H-pyrazol-4-yl)-2H-pyridazin-3-one "A249" ##STR00322## "A250" 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-pyrrolidin-1-ylethoxy)-pyri- midin-2-yl]benzyl}-2H-pyridazin-3-one "A251" 2-[3-(5-ethoxypyrimidin-2-yl)benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-2- H-pyridazin-3-one "A252" ##STR00323## "A253" 6-(3-chlorophenyl)-2-{3-[5-(2-morpholin-4-ylethoxy)pyrimidin-2-yl]b- enzyl}-2H-pyridazin-3-one "A254" ##STR00324## "A255" ##STR00325## "A256" ##STR00326## "A257" 3-(1-{3-[5-(1-methylpiperidin-4-ylmethoxy)pyrimidin-2-yl]-benzyl}-6- -oxo-1,6-dihydropyridazin-3-yl)benzonitrile "A260" 3-(1-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]benzyl}-6-oxo-1,6- -dihydropyridazin-3-yl)benzamide "A261" ##STR00327## "A262" 3-{1-[3-(5-bromopyrimidin-2-yl)benzyl]-6-oxo-1,6-dihydro-pyridazin-- 3-yl}benzonitrile "A263" 3-{1-[3-(5-hydroxypyrimidin-2-yl)benzyl]-6-oxo-1,6-dihydro-pyridazi- n-3-yl}benzonitrile "A264" 3-(6-oxo-1-{3-[5-(piperidin-4-ylmethoxy)pyrimidin-2-yl]benzyl}-1,6-- dihydropyridazin-3-yl)benzonitrile "A265" tert-butyl 4-(2-{3-[3-(3-cyanophenyl)-6-oxo-6H-pyridazin-1-ylmethyl]phenyl}pyrimidin- -5-yloxymethyl)piperidine-l- carboxylate "A266" 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(piperidin-4-yloxy)-pyrimidin-- 2-yl]benzyl}-2H-pyridazin-3-one "A267" 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(piperidin-4-ylmethoxy)-pyrimi- din-2-yl]benzyl}-2H-pyridazin-3-one "A268" ##STR00328## "A269" ##STR00329## "A270" 3-[1-(3-{5-[2-(4-methylpiperazin-1-yl)ethoxy]pyrimidin-2-yl}-benzyl- )-6-oxo-1,6-dihydropyridazin-3-yl]benzonitrile "A271" 3-(1-{3-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzyl}-6-oxo-1,6-dihydr- opyridazin-3-yl)benzonitrile "A272" 3-(1-{3-[5-(3-methoxypropoxy)pyrimidin-2-yl]benzyl}-6-oxo-1,6-dihyd- ropyridazin-3-yl)benzonitrile "A273" 6-(3-fluorophenyl)-2-{3-[5-(1-methylpiperidin-4-ylmethoxy)-pyrimidi- n-2-yl]benzyl}-2H-pyridazin-3-one "A274" 2-{3-[5-(1-methylpiperidin-4-yloxy)pyrimidin-2-yl]benzyl}-6-(1-prop- yl-1H-pyrazol-4-yl)-2H-pyridazin-3-one "A275" 6-(3-chlorophenyl)-2-{3-[5-(1-methylpiperidin-4-ylmethoxy)-pyrimidi- n-2-yl]benzyl}-2H-pyridazin-3-one "A276" ##STR00330## "A276a" ##STR00331## "A277" 5-(1-{3-[5-(1-methylpiperidin-4-yloxy)pyrimidin-2-yl]benzyl}-6-oxo-- 1,6-dihydropyridazin-3-yl)thiophene-2-carboxylic acid "A278" 5-(1-{3-[5-(1-methylpiperidin-4-yloxy)pyrimidin-2-yl]benzyl}-6-oxo-- 1,6-dihydropyridazin-3-yl)thiophene-2-carboxamide "A279" N-methyl-5-(1-{3-[5-(1-methylpiperidin-4-yloxy)pyrimidin-2-yl]-benz- yl}-6-oxo-1,6-dihydropyridazin-3-yl)thiophene-2- carboxamide "A283" methyl (E)-3-(2-{3-[6-oxo-3-(3,4,5-trifluorophenyl)-6H-pyridazin-1-ylmethyl]phen- yl}pyrimidin-5-yl)acrylate "A284" 2-{3-[54(E)-3-aminopropenyl)pyrimidin-2-yl]benzyl}-6-(3,4,5-trifluo- rophenyl)-2H-pyridazin-3-one "A285" 2-{3-[5-(3-aminopropyl)pyrimidin-2-yl]benzyl}-6-(3,4,5-trifluoro-ph- enyl)-2H-pyridazin-3-one "A286" 2-{3-[5-(4-methylpiperazin-1-yl)pyrimidin-2-yl]benzyl}-6-(1-methyl-- 1H-pyrazol-4-yl)-2H-pyridazin-3-one "A287" 3-(1-{3-[5-(4-methylpiperazin-1-yl)pyrimidin-2-yl]benzyl}-6-oxo-1,6- -dihydropyridazin-3-yl)benzonitrile "A288" 3-{6-oxo-1-[3-(5-piperazin-1-ylpyrimidin-2-yl)benzyl]-1,6-dihydropy- ridazin-3-yl}benzonitrile "A289" 6-(4-methanesulfonylphenyl)-2-[3-(5-piperazin-1-ylpyrimidin-2-yl)be- nzyl]-2H-pyridazin-3-one "A290" 4-{1-[3-(5-aminopyrimidin-2-yl)benzyl]-6-oxo-1,6-dihydro-pyridazin-- 3-yl}benzonitrile "A291" 3-{1-[3-(5-aminopyrimidin-2-yl)benzyl]-6-oxo-1,6-dihydro-pyridazin-- 3-yl}benzonitrile "A292" 6-(1-methyl-1H-pyrazol-4-yl)-2-[3-(5-piperazin-1-ylpyrimidin-2-yl)b- enzyl]-2H-pyridazin-3-one "A293" 2-[3-(5-aminopyrimidin-2-yl)benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-2H- -pyridazin-3-one "A294" 2-{3-[5-(2-hydroxyethoxy)pyrimidin-2-yl]benzyl}-6-(1-methyl-1H-pyra- zol-4-yl)-2H-pyridazin-3-one "A295" 3-(1-{3-[5-(3-hydroxypropoxy)pyrimidin-2-yl]benzyl}-6-oxo-1,6-dihyd- ropyridazin-3-yl)benzonitrile "A296" 3-(1-{3-[5-(2-hydroxyethoxy)pyrimidin-2-yl]benzyl}-6-oxo-1,6-dihydr- opyridazin-3-yl)benzonitrile "A297" 2-{3-[5-(3-hydroxypropoxy)pyrimidin-2-yl]benzyl}-6-(1-methyl-1H-pyr- azol-4-yl)-2H-pyridazin-3-one "A298" 3-[1-(1-{3-[5-(3-dimethylaminopropoxy)pyrimidin-2-yl]phenyl}-ethyl)- -6-oxo-1,6-dihydropyridazin-3-yl]benzonitrile "A299" 6-(3,5-difluorophenyl)-2-(1-{3-[5-(3-dimethylaminopropoxy)-pyrimidi- n-2-yl]phenyl}ethyl)-2H-pyridazin-3-one "A300" 6-(3,5-difluorophenyl)-2-((R)-1-{3-[5-(3-dimethylaminopropoxy)-pyri- midin-2-yl]phenyl}ethyl)-2H-pyridazin-3-one "A301" 6-(3,5-difluorophenyl)-2-((S)-1-{3-[5-(3-dimethylaminopropoxy)-pyri- midin-2-yl]phenyl}ethyl)-2H-pyridazin-3-one "A302" 3-(1-{3-[5-(1-methyl-1-oxypiperidin-4-ylmethoxy)pyrimidin-2-yl]-ben- zyl}-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile "A303" 3-(1-{3-[5-(1-formylpiperidin-4-ylmethoxy)pyrimidin-2-yl]-benzyl}-6- -oxo-1,6-dihydropyridazin-3-yl)benzonitrile "A304" ##STR00332## "A305" ##STR00333## "A306" ##STR00334## "A307" ##STR00335## "A308" ##STR00336## "A309" ##STR00337## "A310" ##STR00338## "A311" ##STR00339## "A312" ##STR00340## "A313" ##STR00341## "A314" ##STR00342## or a pharmaceutically acceptable solvate, salt, tautomer or stereoisomer thereof. 14. A pharmaceutical composition according to claim 13, which comprises said compound or a pharmaceutically acceptable solvate, salt, tautomer or stereoisomer thereof in an amount of 1 mg to 700 mg per unit dosage. 15. A pharmaceutical composition according to claim 13, which is in the form of a single dosage unit. 16. A pharmaceutical composition according to claim 13, which comprises said compound or a pharmaceutically acceptable salt thereof. 17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one of the compounds below or a pharmaceutically acceptable solvate, salt, tautomer or stereoisomer thereof in an amount of 0.5 mg to 1 g per unit dosage, wherein the pharmaceutical composition is in the form of one or more dosage units TABLE-US-00021 No. Name and/or structure "A23" ##STR00343## "A30" ##STR00344## "A34" ##STR00345## "A35" ##STR00346## "A36" ##STR00347## "A37" ##STR00348## "A38" ##STR00349## "A39" ##STR00350## "A40" ##STR00351## "A41" ##STR00352## "A42" ##STR00353## "A43" ##STR00354## "A44" ##STR00355## "A44a" ##STR00356## "A45" ##STR00357## "A46" ##STR00358## "A47" ##STR00359## "A48" ##STR00360## "A49" ##STR00361## "A50" ##STR00362## "A52" ##STR00363## "A53" ##STR00364## "A59" ##STR00365## "A63" ##STR00366## "A71" ##STR00367## "A72" ##STR00368## "A73" ##STR00369## "A74" ##STR00370## "A75" ##STR00371## "A77" ##STR00372## "A78" ##STR00373## "A79" ##STR00374## "A84" ##STR00375## "A87" ##STR00376## "A88" ##STR00377## "A89" ##STR00378## "A90" ##STR00379## "A92" ##STR00380## "A95" ##STR00381## "A96" ##STR00382## "A97" ##STR00383## "A98" ##STR00384## "A99" ##STR00385## "A103" ##STR00386## "A104" ##STR00387## "A105" ##STR00388## "A106" ##STR00389## "A107" ##STR00390## "A108" ##STR00391## "A109" ##STR00392## "A110" ##STR00393## "A111" ##STR00394## "A112" ##STR00395## "A113" ##STR00396## "A114" ##STR00397## "A115" ##STR00398## "A116" ##STR00399## "A117" ##STR00400## "A118" ##STR00401## "A119" ##STR00402## "A120" ##STR00403## "A121" ##STR00404## "A123" ##STR00405## "A124" ##STR00406## "A125" ##STR00407## "A126" ##STR00408## "A129" ##STR00409## "A131" ##STR00410## "A142" ##STR00411## "A143" ##STR00412## "A149" ##STR00413## "A150" ##STR00414## "A151" ##STR00415## "A154" ##STR00416## "A155" ##STR00417## "A156" ##STR00418## "A157" ##STR00419## "A158" ##STR00420## "A159" ##STR00421## "A160" ##STR00422## "A161" ##STR00423## "A162" ##STR00424## "A163" ##STR00425## "A164" ##STR00426## "A165" ##STR00427## "A166" ##STR00428## "A167" ##STR00429## "A168" ##STR00430## "A169" ##STR00431## "A170" ##STR00432## "A171" ##STR00433## "A174" ##STR00434## "A175" ##STR00435## "A176" ##STR00436## "A180" ##STR00437## "A182" ##STR00438## "A184" ##STR00439## "A186" ##STR00440## "A187" ##STR00441## "A188" ##STR00442## "A188a" ##STR00443## "A190" ##STR00444## "A215" ##STR00445## "A217" ##STR00446## "A225" ##STR00447## "A227" ##STR00448## "A228" ##STR00449## "A244" ##STR00450## "A246" ##STR00451## "A247" ##STR00452## "A249" ##STR00453## "A252" ##STR00454## "A254" ##STR00455## "A255" ##STR00456## "A256" ##STR00457## "A261" ##STR00458## "A268" ##STR00459## "A269" ##STR00460## "A276" ##STR00461## "A276a" ##STR00462## "A304" ##STR00463## "A305" ##STR00464## "A306" ##STR00465## "A307" ##STR00466## "A308" ##STR00467## "A309" ##STR00468## "A310" ##STR00469## "A311" ##STR00470## "A312" ##STR00471## "A313" ##STR00472## "A314" ##STR00473## or a pharmaceutically acceptable solvate, salt, tautomer or stereoisomer thereof. 18. A pharmaceutical composition according to claim 17, which comprises said compound or a pharmaceutically acceptable solvate, salt, tautomer or stereoisomer thereof in an amount of 1 mg to 700 mg per unit dosage. 19. A pharmaceutical composition according to claim 17, which is in the form of a single dosage unit. 20. A pharmaceutical composition according to claim 17, which comprises said compound or a pharmaceutically acceptable salt thereof.